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ABSTRACT
Lipopolysaccharide (LPS) contributes to asthma exacerbations
and development of inhaled corticosteroid insensitivity. Complete
resistance to systemic corticosteroids is rare, and most patients
lie on a continuum of steroid responsiveness. This study aimed to
examine the sensitivity of combined ovalbumin- (Ova) and LPS-
induced functional and inflammatory responses to inhaled and
systemic corticosteroid in conscious guinea pigs to test the
hypothesis that the route of administration affects sensitivity.
Guinea pigs were sensitized to Ova and challenged with inhaled
Ova alone or combinedwith LPS. Airway function was determined
by measuring specific airway conductance via whole-body pleth-
ysmography. Airway hyper-responsiveness to histamine was
determined before and 24 hours post-Ova challenge. Airway
inflammation and underlying mechanisms were determined from
bronchoalveolar lavage cell counts and lung tissue cytokines.
Vehicle or dexamethasone was administered by once-daily i.p.
injection (5, 10, or 20 mg/kg) or twice-daily inhalation (4 or 20
mg/ml) for 6 days before Ova challenge or Ova with LPS. LPS
exacerbated Ova-induced responses, elongating early asthmatic
responses (EAR), prolonging histamine bronchoconstriction, and
further elevating airway inflammation. Intraperitoneal dexametha-
sone (20 mg/kg) significantly reduced the elongated EAR and
airway inflammation but not the increased bronchoconstriction to
histamine. In contrast, inhaled dexamethasone (20 mg/ml), which
inhibited responses to Ova alone, did not significantly reduce
functional and inflammatory responses to combined Ova and
LPS. Combined Ova and LPS–induced functional and inflam-
matory responses are insensitive to inhaled, but they are only
partially sensitive to systemic, dexamethasone. This finding
suggests that the route of corticosteroid administration may be
important in determining corticosteroid sensitivity of asthmatic
responses.
Introduction
Corticosteroids are a mainstay of asthma treatment owing
to their ability to reduce the late asthmatic response (LAR),
airway hyper-responsiveness (AHR), and inflammatory re-
sponses to allergens (Palmqvist et al., 2005). Inhaled cortico-
steroids are used in regular maintenance therapy, whereas
systemically administered corticosteroids are used in patients
not achieving symptomatic control with standard treatments
or experiencing an exacerbation (Boulet et al., 2015). The
mechanism underlying the decreased responsiveness to in-
haled corticosteroids in these patients is unknown, but several
studies have indicated that lipopolysaccharide (LPS) contrib-
utes to both asthma exacerbations and the development of
corticosteroid insensitivity (Goleva et al., 2008, 2013).
It is estimated that 5% of patients with asthma are
corticosteroid-insensitive, but full resistance is rare, and most
patients lie on a spectrum of responsiveness (Szefler et al.,
2002; Bossley et al., 2009). In patients who are insensitive to
inhaled corticosteroids, systemic corticosteroids, usually given
orally, are often still effective (Ten Brinke et al., 2004; Hodgson
et al., 2012). The continued effectiveness of oral corticosteroids
may be due to suppression of inflammatory cells in the blood
and bonemarrow. In the bonemarrow, corticosteroids suppress
the maturation of hemopoietic cells, including eosinophils, an
important cell type recruited to the airways in allergic asthma
(Mao et al., 2004; Ben et al., 2008). Additionally, inflammatory
cells, such as neutrophils, an important cell type in asthma
exacerbations, aremore corticosteroid-sensitive in the systemic
circulation than in the lungs (Plumb et al., 2012). Inhaled cor-
ticosteroids can also access the systemic circulation and suppress
inflammatory cell maturation in the bonemarrow, depending on
the dose and pharmacokinetics of the corticosteroid (Wood et al.,
1999; Martin et al., 2002; Shen et al., 2002); however, access to
the systemic circulation appears to decrease with increasing
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severity of asthma, thereby restricting the distribution of inhaled
corticosteroids to the airways (Wood et al., 1999; Brutsche et al.,
2000; Harrison and Tattersfield, 2003). Therefore, the tissue
distribution of a corticosteroidmay be an important determinant
of the extent of inflammatory suppression.
Our previous study demonstrated that combining ovalbu-
min (Ova) with LPS challenge in sensitized guinea pigs in-
creased the inflammatory and functional responses to allergen
(Lowe et al., 2015). Moreover, it rendered these responses
insensitive to doses of inhaled fluticasone propionate (FP) that
were effective against functional and inflammatory responses to
Ova alone (Lowe et al., 2015). A previous study by Komlósi et al.
(2006) suggested that LPS decreases, but does not abolish, the
sensitivity of Ova-induced inflammatory responses to i.p. dexa-
methasone; however, this study used a different combination of
Ova and LPS and animal species (mice), making it difficult
to generalize the findings to the guinea pig model we have
developed. To our knowledge, no previous study has directly
compared the sensitivity of allergen-induced functional and
inflammatory responses to systemic and inhaled corticosteroids
in a model of asthma or asthma exacerbation. Therefore, in the
present study, we extend our earlier studies demonstrating
insensitivity to inhaled fluticasone by examining the hypothesis
that the functional and inflammatory responses induced by
combining Ova and LPS demonstrate different sensitivities to
inhaled and systemic dexamethasone. Ova and LPS are triggers
for the inflammatory responses of the adaptive and innate
immune systems, respectively. To identify possible underlying
mechanisms for the steroid insensitivity and any differences with
route of administration, we examined the lung levels of the
cytokines interleukin (IL) IL-8, IL-13, and IL-17. IL-8 and IL-17
are released from macrophages and Th2 lymphocyte, respec-
tively, and are involved in neutrophil chemotaxis (Ciepiela et al.,
2015). IL-13 is released from macrophages and is involved in
airway hyper-reactivity (Cockcroft and Davis, 2006).
Materials and Methods
Study Design. Guinea pigs (male, Dunkin-Hartley, 200–300 g;
Charles River, Munich, Germany) were sensitized by i.p. injection of
Ova (150mg) andAl(OH)3 (100mg) in saline (1ml) on days 1, 4, and 7 of
the Ova protocols. They were challenged with inhaled ovalbumin
(300 mg/ml) or saline on day 21 in groups of six held in a Perspex
exposure chamber (38  20  20 cm) using a DeVilbiss nebulizer at
0.3 ml/min and pressure of 20 psi (Fig. 1A). LPS (30 mg/ml) or saline
inhalation challenge was performed 48 hours pre-Ova and coadminis-
tered with Ova challenge (Fig. 1B). Nonsensitized guinea pigs were
also exposed to LPS (30 mg/ml) or saline on days 5 and 7 (Fig. 1C).
Procedures were performed according to the Animals Act of 1986 (Sci-
entific Procedures) and underwent ethical review by Cardiff University
Biologic Standards Committee. The design and execution of the study
followed Animal Research Reporting of In Vivo Experiments guidelines
(McGrath et al., 2010).
Airway Function Measurement. Airway function was mea-
sured as specific airway conductance (sGaw) in conscious, spontane-
ously breathing guinea pigs by plethysmography (Buxco Systems,
DSI, St. Paul, MN). Lung function was recorded after final Ova, LPS,
or saline challenge at intervals of 12 hours. Airways responses to
aerosolized histamine were determined before and 24 hours after Ova
or the final LPS/saline challenge using whole-body plethysmography.
Histamine (0.3 mM, 2 minutes) was delivered by the use of a Buxco
nebulizer chamber at 0.5 liters/minute and 10% duty (percentage every
6 seconds of nebulizing) per chamber.Histaminewas selected tomeasure
airways reactivity because it caused dose-related bronchoconstriction
(0.1, 0.3, 0.5, and 0.9mM) (unpublished data) in guinea pigs in our hands
in naïve guinea pigs, the selected dose (0.3 mM) evoking minimal
bronchoconstriction, which allowed for increases to be observed when
there is hyper-reactivity. Lung function was measured before histamine
inhalation and at 0, 5, and 10 minutes afterward.
Bronchoalveolar Lavage. After the final histamine challenge,
guinea pigs were sacrificed by an overdose of sodium pentobarbi-
tone (Euthatal, 400 mg/kg, i.p.; Merial, Harlow, UK). Subsequently,
bronchoaleveolar lavage of the whole lung was performed using saline
(1 ml/100 g of guinea pig weight) instilled through a polypropylene
cannula, inserted into the trachea, and left for 3 minutes. This process
was repeated, and samples were pooled. Total cell numbers per
milliliter were determined using a Neubauer hemocytometer. Leuko-
cytes subpopulations of eosinophils, macrophages, neutrophils, and
lymphocytes were determined from undiluted lavage fluid smears on
glass microscope slides produced by a Shandon cytospin and subsequent
staining with 1.5% Leishman’s solution in 100%methanol for 6minutes.
A minimum of 200 leukocyte cells were counted. Airway edema was
determined by measuring lavage fluid protein content by BCA protein
assay per themanufacturer’s instructions (Pierce ProteinBiology, Fisher
Scientific, Loughborough UK). Levels of IL-8, IL-13, and IL-17 were
measured by enzyme-linked immunosorbent assay (R&D Systems,
Abingdon, UK) using human antibodies on diluted homogenized lung
samples. Human antibodies were used to prepare the standard curves.
The use of human cytokine antibodies was selected formeasuring guinea
pig cytokines because at the time of performing these studies, the
available guineapig antibodies andkitswereuntried andunreliable. The
human antibodies were effective in detecting and quantifying cytokines
IL-8, IL-13, and IL-17 in guinea pig lung tissue, but there was no cross-
reactivity with human IL-5, IL-12p70, interferon-g, and IL-10, which
were not therefore measured. Lung samples were prepared from 100mg
of right middle lung lobe using standard methods described previously
(Thomas et al., 2011). Assays were carried out per the manufacturer’s
instructions. The detection limits were 31 pg/ml for IL-8, 47 pg/ml for
IL-13, and 16 pg/ml for IL-17. Cytokine levelswere adjusted for total lung
protein and expressed as picograms or nanograms per milligram of lung
protein.
Drug Administration. All chemicals were obtained from Sigma-
Aldrich (Gillingham, UK) or Fisher-Scientific (Loughborough, UK)
unless stated otherwise. Ovalbumin prepared from chicken eggs by ion
Fig. 1. Protocols for Ova and LPS challenge: (A) Ova challenge, (B) Ova +
LPS cochallenge, and (C) LPS challenge of naïve guinea pigs.
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exchange (VWR International Ltd, Leicestershire, UK) was dissolved
in saline with Al(OH)3 in suspension and stirred for at least 2 hours
before injection.
Dexamethasone or vehicle was administered either by i.p. injection
or inhalation (Fig. 1). Vehicle [25% dimethylsulfoxide, 75% saline] or
dexamethasone (5, 10, or 20 mg/kg) was administered by once-daily
bilateral i.p. injection (0.5 ml each side). Inhaled vehicle (30% ethanol,
30% dimethylsulfoxide, 40% saline) or dexamethasone (4 or 20mg/ml)
was administered by nebulizer for 15 minutes twice daily into a
Perspex whole-body exposure chamber (38  20 20 cm) exposing six
animals at a time, using the same DeVilbiss nebulizer used for Ova
challenge. The mass median aerodynamic diameter of the particles
generated by this system was 2.79 6 0.22 mm. Drug administration
took place from days 16 to 21 in Ova protocols and days 2 to 7 in LPS-
only protocols, 30 minutes before any Ova or LPS administration.
Data Analysis. Lung function datawere plotted as a percentage of
baseline sGaw. The EAR (0–6 hours) and LAR (6–12 hours) were
expressed as the peak bronchoconstriction, displayed as a histogram
next to the time course and as area under the curve to account for
differences in the timing and duration of the allergen responses.
The duration of the EARwas also analyzed as the time taken to return
to 50% of peak EAR sGaw values. Results are plotted as the mean 6
S.E.M.
Student’s t tests were used for the comparison of differences
between two groups or data points. One-way analysis of variance
(ANOVA) followed by Dunnett’s post-test was used when two or more
groups were being compared with a control group or Bonferroni post-
test when two or more groups were being compared with each other. A
two-way ANOVA was not considered appropriate for comparisons
between time courses as we were not interested in whether there were
differences between responses at different times but between treat-
ments. It would be too severe a test and likely to yield type 2 errors (no
differences detected between treatments when there were clear
differences at individual time points, such as the peaks of EAR and
LAR). The nonparametric Kruskal-Wallis ANOVA or Mann–Whitney
U tests were used where appropriate for data that did not display
equal variances. No statistical comparisons were made between
Ova 1 LPS and LPS alone because the experimental conditions
were very different, LPS being examined in naïve unsensitized
animals and Ova1 LPS in sensitized animals. P values less than 0.05
were considered significant.
Results
Effect of LPS Challenge on Ova-Induced Functional and
Inflammatory Responses
Saline challenge produced no significant changes to the
baseline sGaw over 12 hours (Fig. 2A). Ova challenge induced
an immediate bronchoconstriction, characteristic of the EAR
and a second bronchoconstriction at 9 to 10 hours indicative
of a LAR (Fig. 2A). The addition of LPS to Ova challenge
increased the duration of theEAR (Fig. 2A) and increased time
to reach a 50% reduction in peak EAR sGaw (Fig. 2B). LPS
alone induced a bronchoconstriction lasting 4 hours, the peak
being significantly greater (235.7% 6 2.7%) than with saline
challenge (219.5%6 4.8%) (data not shown, but compare with
vehicle-treated animals shown in Fig. 3E).
Ova challenge induced AHR, demonstrated by a significant
increase in the immediate bronchoconstriction by histamine
24 hours after Ova challenge (Fig. 2C). The addition of LPS to
Ova challenge altered the bronchoconstrictor response to
histamine 24 hours after Ova inhalation, with continued,
progressive, significant decreases in sGaw from 0 to 10 min-
utes after histamine challenge (Fig. 2D). Saline challenge did
not significantly change the bronchoconstrictor response to
histamine (Fig. 2E), but it was significantly increased 24 hours
after challenge with LPS alone (Fig. 2F). When Ova challenge
was compared with naïve guinea pigs, there were significant
increases in total cells, macrophages, eosinophils, and lym-
phocytes (Fig. 2,G–J). IL-13 (8.76 1.2 ng/mg vs. 3.46 0.5 ng/mg)
and IL-17 (113.5 6 5.7 ng/mg vs. 41.9 6 15.4 ng/mg) levels
were also significantly increased after Ova challenge com-
pared with naïve guinea pigs, respectively (data not shown).
Lavage fluid protein levels and IL-8 levels were unchanged by
Ova challenge (data not shown). The addition of LPS to Ova
challenge further increased total cells, macrophages, and neu-
trophils compared with Ova alone (Fig. 2, G, H, and K). Lung
IL-8 (38.66 3.4 pg/mg vs. undetectable, respectively) and lavage
fluid protein (4.2 6 0.5 ng/mg vs. 0.4 6 0.1 ng/mg, respectively)
were also significantly increasedwith the addition of LPS toOva
(data not shown). Eosinophils (Fig. 2I) and cytokine IL-13 and
IL-17 levels (data not shown) were unchanged by the addition of
LPS to Ova challenge. LPS challenge alone significantly in-
creased total cells,macrophages, and neutrophils comparedwith
saline challenge (Fig. 2, G, H, andK). Lavage fluid protein (3.26
0.3 ng/mg vs. 0.4 6 0.1 ng/mg) and IL-8 (25.4 6 3.3 pg/mg vs.
undetectable) were also significantly increased compared with
saline (data not shown).
Inhaled and Intraperitoneal Dexamethasone on Early
and Late Asthmatic Responses.
Intraperitoneal dexamethasone. Ova challenge in vehicle-
treated guinea pigs induced an EAR and LAR, the latter being
significantly reduced by i.p. dexamethasone, 20mg/kg (Fig. 3A),
but not by the 5- or 10-mg/kg doses (221.4%6 7.4%,221.3%6
2.0%, respectively) compared with vehicle (222.6% 6 1.9%;
data not shown). In Ova1 LPS groups, i.p. dexamethasone
(20 mg/kg) reduced the duration of the extended EAR, with a
significant reduction in the bronchoconstriction between 1 and
3 hours after Ova challenge, but not the peak EAR or LAR (Fig.
3B). This result was revealed as a significantly reduced time to
50% recovery of the EAR (Fig. 3C). In the Ova-alone groups,
the area-under-the-curve (AUC) analysis revealed signifi-
cant reductions in the EAR and LAR with i.p. dexamethasone
20 mg/kg compared with vehicle. In Ova 1 LPS groups, i.p.
dexamethasone (20mg/kg) significantly reduced theEARAUC,
but not the LAR (Fig. 3D). LPS challenge alone in vehicle-
treated animals elicited bronchoconstriction 0–4 hours post-
exposure, peaking at 3 hours (Fig. 3E), which along with AUC
(Fig. 3D) was significantly attenuated by i.p. dexamethasone
(20 mg/kg).
Inhaled dexamethasone. In Ova-alone groups, the peak
EAR was significantly attenuated by inhaled dexamethasone
(20mg/ml) (257.9%6 3.6%) comparedwith vehicle (270.8%6
2.6%, respectively) Fig. 4A), but not by the lower dose (4mg/ml)
of inhaled dexamethasone (273.2% 6 2.7%; data not shown).
The peak LAR was also attenuated by inhaled dexamethasone
(20 mg/ml) (211.1%6 2.0%) compared with vehicle (221.3%6
2.6%) (Fig. 4A) but not by inhaled dexamethasone, 4 mg/ml
(221.3%6 2.6%; data not shown). InOva1LPS groups, inhaled
dexamethasone (20 mg/ml) significantly increased the broncho-
constriction 0–1 hour postchallenge (e.g., 15 minutes:261.8%6
3.1%) compared with vehicle (248.3% 6 3.1%) (Fig. 4B) and
the peak (63.7% 6 2.4% vs. 255.6% 6 3.6%, respectively),
but it did not affect AUC or recovery of the EAR or the LAR
(Fig. 4, C and D). In LPS only groups, the bronchoconstriction
induced by LPS challenge was also insensitive to inhaled
dexamethasone (20 mg/ml) (Fig. 4E). Inhaled vehicle reduced
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Fig. 2. Guinea pigs were sensitized with Ova and challenged with Ova or saline alone or Ova + LPS, or unsensitized guinea pigs were challenged with
LPS. (A) Mean time courses for changes in sGaw. Histograms represent the maximum bronchoconstriction values recorded during the EAR (0–6 hours)
and LAR (6–12 hours); mean changes in sGaw are expressed as mean 6 S.E.M. percent change from baseline before Ova challenge. (B) Analysis of the
time taken for EAR to recover to 50% of peak bronchoconstriction values. (C and F) Response of the airways to nebulized histamine (0.3 mM, 2 minutes)
24 hours before and 24 hours after (C) Ova and (D) Ova + LPS challenge; (E) the second saline challenge; (F) the second LPS challenge. Histograms
represent themean peak response (G) total cell, (H) macrophage, (I) eosinophil, (J) lymphocyte, and (K) neutrophil counts in bronchoalveolar fluid. Naïve
(unsensitized and unchallenged) groups are also shown for comparative purposes only; n = 6 or 7. *Significantly different from Ova challenge or
prehistamine challenge where appropriate, P , 0.05; ** P , 0.01; ***P , 0.001; ^^significantly different from naïve, P , 0.01, ^^^ P , 0.001;
†††Significantly different from saline, P , 0.001; performed with a two-tailed t test or one-way ANOVA, followed by Bonferroni or Kruskal-Wallis
ANOVA post-test where appropriate.
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the peak bronchoconstriction to LPS comparedwith i.p. vehicle,
suggesting inhibitory effects of daily inhaled vehicle uponairway
function responses to LPS.
Inhaled and Intraperitoneal Dexamethasone on
Airway Hyper-responsiveness.
Intraperitoneal dexamethasone. Ova alone in i.p. vehicle-
treated guinea pigs induced AHR as an increase in broncho-
constriction in response to histamine (Fig. 5A). This response
was attenuated by i.p. dexamethasone, 10 mg/kg (postchal-
lenge, 212.6% 6 3.7% vs. prechallenge, 212.0% 6 2.1%; data
not shown) and 20 mg/kg (Fig. 5B), but not the 5 mg/kg dose
(data not shown). In the Ova 1 LPS groups, the prolonged
bronchoconstrictor response to histamine in vehicle-treated
guinea pigs (Fig. 5C) was not significantly reduced by i.p.
dexamethasone, 20 mg/kg (Fig. 5D). The increased bronchocon-
strictor response after LPS challenge alone in vehicle-treated
guinea pigs (Fig. 5E) was abolished by i.p. dexamethasone,
20 mg/kg (Fig. 5F).
Inhaled dexamethasone. In inhaled vehicle-treated guinea
pigs, Ova alone increased the bronchoconstriction resulting
from histamine (Fig. 6A). This increase was significantly
attenuated with inhaled dexamethasone, 4 mg/ml (postchal-
lenge, 215.5% 6 4.1% versus prechallenge, 210.1% 6 5.3%;)
(data not shown) and 20 mg/ml (Fig. 6B). In the Ova 1 LPS
groups, the significantly increased peak bronchoconstrictor
response to histamine in inhaled vehicle-treated guinea pigs
(Fig. 6C) was unchanged by inhaled dexamethasone (20mg/ml)
(Fig. 6D). Similarly, in the LPS-alone groups, the increased
response to histamine in inhaled vehicle-treated guinea pigs
(Fig. 6E) was not significantly attenuated by inhaled dexa-
methasone (20 mg/kg) (Fig. 6F).
Inhaled and Intraperitoneal Dexamethasone on
Airway Inflammation.
Intraperitoneal dexamethasone. Ova challenge alone of
vehicle-treated animals increased total cells and all individual
cell types (Fig. 7, A–E). It also increased total protein in lavage
fluid and levels of the cytokines IL-13 and IL-17 (Fig. 7, H and
I). Intraperitoneal dexamethasone (20 mg/kg) reduced total
cells (Fig. 7A), macrophages (Fig. 7B), eosinophils (Fig. 7C),
and lymphocytes (Fig. 7D) compared with vehicle. Neutrophils
were not changed by any dose of dexamethasone (Fig. 7E).
Lavage fluid protein was significantly reduced by i.p. dexa-
methasone, 10 mg/kg (1.26 0.1 mg/ml; data not shown) and
20 mg/kg (Fig. 7F), but not 5 mg/kg, compared with vehicle
(1.7 6 0.2 mg/ml)(data not shown). IL-8 was not detectable in
samples from naïve or Ova-challenged guinea pigs and is
therefore not shown. Intraperitoneal dexamethasone (20 mg/kg)
significantly decreased both IL-13 (Fig. 7H) and IL-17 (Fig. 7I)
compared with vehicle treatment.
In Ova 1 LPS groups, i.p. dexamethasone (20 mg/kg)
significantly reduced the total cells and all individual cell
types compared with vehicle treatment (Fig. 7, A–E). Lavage
fluid protein was also significantly reduced with i.p. dexa-
methasone (20 mg/kg) to nearly naïve levels compared with
vehicle treatment (Fig. 7F). In contrast, IL-8, IL-13, and IL-17
were not significantly reduced by i.p. dexamethasone (20 mg/kg)
(Fig. 7, G–I).
In the LPS-alone group, i.p. dexamethasone (2 mg/kg)
significantly reduced total cells (Fig. 7A), eosinophils (Fig.
7C), and neutrophils (Fig. 7E) compared with vehicle treat-
ment. Significant decreases in lavage fluid protein (Fig. 7F) and
IL-8 (Fig. 7G) with i.p. dexamethasone (20 mg/kg) compared
with vehicle treatment were also observed.
Inhaled dexamethasone. Ova alone increased total cells,
macrophages, eosinophils, lymphocytes, lavage fluid protein,
Fig. 3. Guinea pigs were sensitized with ovalbumin (Ova) and challenged
with (A) Ova alone or (B) Ova + LPS or unsensitized guinea pigs challenged
withLPSand treatedwith once-daily i.p. vehicle or dexamethasone (20mg/kg).
(A and B) Mean time courses for changes in sGaw. Histograms represent
the maximum bronchoconstriction values recorded during the EAR (0–6
hours) and LAR (6–12 hours); mean changes in sGaw are expressed as
mean 6 S.E.M. percent change from baseline before Ova challenge. (C)
Analysis of the time taken for the EAR to recover to 50% of peak
bronchoconstriction values. (D) AUC analysis of sGaw values for 0–12
hours, 0–6 hours, and 6–12 hours post-Ova challenge; also shown are
data for naïve guinea pigs challenged with LPS; (E) mean time courses
for changes in sGaw for naïve guinea pigs treated with LPS; n = 6 to 7;
*Significantly different from vehicle treatment, P , 0.05; **P , 0.01;
***P , 0.001; performed with one-way ANOVA followed by Dunnett’s
post-test.
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IL-13, and IL-17 in vehicle-treated guinea pigs compared
with naïve guinea pigs (Fig. 8, A–D, F, H, and I). Inhaled
dexamethasone (4 mg/ml) reduced total cell numbers (6.1 6
0.7  106/ml) compared with vehicle treatment (9.1 6 1.1 
106/ml) and eosinophils (2.1 6 0.3  106/ml) compared with
vehicle treatment (4.1 6 0.8  106/ml; data not shown).
Inhaled dexamethasone (20 mg/ml) also significantly re-
duced total cells (Fig. 8A) and eosinophils (Fig. 8C) compared
with vehicle treatment. Additionally, inhaled dexamethasone
(20 mg/ml) significantly reduced macrophages (Fig. 8B) and
lavage fluid protein (Fig. 8F). IL-8 was not detectable after
Ova alone and is therefore not shown. IL-13 and IL-17 were
reduced by dexamethasone (20 mg/ml), but this decrease was
not statistically significant (Fig. 8, H and I).
In theOva1LPSgroups, inhaled dexamethasone (20mg/ml)
did not significantly reduce any leukocytes or cytokines
measured; however, inhaled dexamethasone (20 mg/ml) signif-
icantly increased total cell numbers compared with vehicle
treatment (Fig. 8A), with a corresponding increase in macro-
phages (Fig. 8B). In contrast, lavage fluid protein was signifi-
cantly reduced by inhaled dexamethasone (20mg/ml) compared
with vehicle (Fig. 8F). It is worth noting that in the vehicle-
treated groups, the addition of LPS to Ova did not increase the
numbers of eosinophils as seen in untreated animals (Fig. 2I) or
in animals treated with i.p. vehicle (Fig. 7C). This was probably
not due to inconsistency of the eosinophil response but to an
effect of inhaled vehicle. Similarly, LPS alone induced pulmo-
nary inflammation and lavage fluid protein, and IL-8 levels
were unchanged with inhaled dexamethasone (20 mg/ml)
(Fig. 8, A–G).
Discussion
This study is the first to demonstrate directly that cortico-
steroid insensitivity varies according to the route of adminis-
tration in an animal model of asthma exacerbation. It also
demonstrated a divergence between functional responses,
such as AHR, and inflammatory responses in their sensitivity
to corticosteroids. This study may have important implica-
tions for the future treatment of corticosteroid-insensitive
asthma and improve understanding of why oral corticoste-
roids are an effective rescue medication in patients who do not
respond to high-dose inhaled corticosteroids.
Inhaled and systemic corticosteroids are effective at re-
ducing allergen-induced inflammatory and functional re-
sponses in guinea pigs (Toward and Broadley, 2004; Evans
et al., 2012; Ford et al., 2013). Dose-response assessment of
dexamethasone onOva-induced functional responses revealed
that the highest doses of inhaled (20mg/ml) and i.p. (20mg/kg)
dexamethasone reduced the LAR and AHR. The processes
underlying functional responses are initiated during the EAR
and mediated by inflammatory cell, including eosinophils,
macrophages and lymphocytes, and cytokines, including IL-5
and IL-13 (Gauvreau et al., 2000; Toward and Broadley, 2004;
Bradding et al., 2006). Correspondingly, these cell types were
all reduced in Ova groups by the highest doses of dexameth-
asone. IL-13 and IL-17 levels were also reduced by dexameth-
asone, although statistically significant reductions were
demonstrated only with i.p. dexamethasone. This dose was
then used to examine the corticosteroid sensitivity of func-
tional and inflammatory responses to combined Ova 1 LPS
challenge. The addition of LPS to Ova challenge elongated the
EAR, prolonged the bronchoconstrictor response to histamine,
and increased airway inflammation, confirming the findings
of our previous study (Lowe et al., 2015). Unlike with Ova
challenge alone, functional and inflammatory responses to
Ova 1 LPS were differentially sensitive to inhaled and i.p.
dexamethasone. Airway inflammation and the prolongedEAR
were decreased by i.p. dexamethasone, but AHR and LAR
were not. By contrast, both functional and inflammatory re-
sponses were insensitive to inhaled dexamethasone, confirming
Fig. 4. Guinea pigs were sensitized with Ova and challenged with (a) Ova
alone or (B) Ova + LPS and treated with twice-daily inhaled vehicle or
dexamethasone (20 mg/ml). Histograms represent the maximum bron-
choconstriction values recorded during the EAR (0–6 hours) and LAR
(6–12 hours); mean changes in sGaw are expressed as mean 6 S.E.M.
percent change from baseline before Ova challenge. (C) Analysis of time
taken for the EAR to recover to 50% of peak bronchoconstriction values;
(D) AUC analysis of sGaw values for 0–12 hours, 0–6 hours, and 6–12
hours post-Ova challenge; also shown are data for naïve guinea pigs
challenged with LPS; n = 6 or 7. *Significantly different from vehicle
treatment P , 0.05; **P , 0.01; ***P , 0.001; performed with one-way
ANOVA followed by Dunnett’s post-test.
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our previous findings (Lowe et al., 2015) with FP in this model.
The overall finding is that corticosteroid insensitivity in this
model is dependent on the route of administration.
The EAR is mediated by basophils and mast cells and has
been demonstrated to be insensitive to inhaled FP in humans
and guinea pigs (Palmqvist et al., 2005; Evans et al., 2012;
Lowe et al., 2015). In contrast, the present study shows that
recovery of the EAR after Ova alone was reduced by dexa-
methasone administered by both the inhaled and the i.p.
routes without any effect on the peak EAR. In the Ova 1 LPS
group, however, the duration of the elongated EAR was
reduced by i.p. dexamethasone but not by inhaled dexameth-
asone. This finding suggests that a component of the Ova
alone–induced EAR is corticosteroid-sensitive and that the
process that mediates the elongated EAR after Ova 1 LPS
challenge is also sensitive to systemic corticosteroid. The
sensitivity of Ova 1 LPS responses to dexamethasone corre-
sponds with the sensitivity to dexamethasone of the broncho-
constriction induced by LPS alone, which was also reduced by
i.p. but not inhaled dexamethasone. Correspondingly, neutro-
phils, but not macrophages, were reduced in the group given
LPS alone, suggesting they may be a mediator of this re-
sponse. This observation is supported by a study in mice,
which also demonstrated an association between neutrophil
depletion using vinblastine and a reduction in the broncho-
constriction to LPS (Lefort et al., 2001). Thus, temporal
overlap between the LPS- and Ova-induced bronchoconstric-
tions may explain why the EAR in the Ova 1 LPS groups is
partially sensitive to systemic corticosteroid. Furthermore,
the insensitivity of the elongated EAR response in the Ova 1
LPS groups to inhaled dexamethasone suggests that the
elongated EAR is mediated in part by factors external to the
lung. Histamine and several other substances released from
airway mast cells are generally considered mediators of the
EAR. Therefore, decreased airway mast cell numbers or
histamine release is unlikely to mediate the elongated EAR,
as these cells are localized to the airways and would be
expected to be equally sensitive to both routes of corticosteroid
administration (Toward and Broadley, 2004; James et al.,
2012).
Other functional responses, including AHR and the LAR,
were rendered insensitive to both routes of dexamethasone
administration with the addition of LPS to airways challenge
with Ova. Therefore, these findings confirm that the cortico-
steroid insensitivity of the AHR and LAR after Ova 1 LPS is
not specific to FP or the inhaled route of administration (Lowe
et al., 2015). A previous study has also demonstrated a similar
insensitivity of AHR to i.p. dexamethasone in Ova1 LPS–
challengedmice (Komlósi et al., 2006). As both theLARandAHR
have been demonstrated to be associated with airway inflam-
mation (Gauvreau et al., 2000; Toward and Broadley, 2004;
Dente et al., 2008), it is interesting that Komlósi et al. (2006)
found that eosinophils, macrophages, and lymphocytes remained
corticosteroid-sensitive; however, the absolute numbers of in-
flammatory cells remained high and similar to counts in Ova 1
vehicle groups. Both findings are supported in the current study
and may indicate that the remaining inflammatory cell popula-
tion is still sufficient and actively releasing mediators, such as
interferon-g and IL-13, that promote bronchoconstriction (Yang
et al., 2009; Kinyanjui et al., 2013). Alternatively, free radicals
generated from macrophages and neutrophils may produce
epithelial damage, resulting in corticosteroid insensitive-AHR
in theOva1LPSgroups. Epithelial damage disrupts themetab-
olism of bronchoconstrictive substances such as histamine,
explaining the increased length of histamine-induced broncho-
constrictions (Hoshi et al., 1996; Haddad, 2004). Moreover,
Fig. 5. Responses of airways to nebulized histamine
delivered in a plethysmograph (0.3 mM, 2 minutes) to
guinea pigs (A and B) sensitized and challenged with Ova
and treated with once-daily i.p. (A) vehicle or (B) dexa-
methasone (20 mg/kg); (C and D) sensitized and challenged
with Ova + LPS treated with once-daily i.p. (C) vehicle or
(D) dexamethasone (20 mg/kg); (E and F) challenged with
LPS and treated with once-daily i.p. (E) vehicle or (F)
dexamethasone, 20 mg/kg. Histograms represent the mean
peak response to histamine before and after Ova, Ova +
LPS, or LPS challenge. Mean changes in sGaw are
expressed as mean 6 S.E.M. percent change from baseline.
A negative value represents a bronchoconstriction. n = 6 or
7. *Significantly different from vehicle treatment P , 0.05;
**P , 0.01; ***P , 0.001; performed with a two-tailed
t test.
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epithelial wound closure has been reported to be unaffected or
even suppressed by corticosteroids, whichwouldmean thatAHR
mediated by this mechanism would likely be corticosteroid-
insensitive (Dorscheid et al., 2006) (http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3615997/). Additionally, epithelial disruption
may expose the underlying parasympathetic nerves and in-
crease neural reflexes in the airways, promoting the LAR in rats
and guinea pigs (Raemdonck et al., 2012; Smit et al., 2014).
The sensitivity of Ova 1 LPS-induced responses coincided
with the sensitivity of LPS-induced responses to inhaled and
systemic dexamethasone, suggesting insensitivity in the Ova
1 LPS model may be the result of intrinsic insensitivity after
LPS. Consistent with previous studies, LPS responses were
demonstrated to be insensitive to inhaled dexamethasone but
sensitive to systemic dexamethasone (O’Leary et al., 1996;
Trapp et al., 1998; Toward and Broadley, 2004); however, the
lack of sensitivity to i.p. dexamethasone—such as AHR in Ova
1 LPS compared with LPS groups—suggests that the effect of
LPS on Ova-induced responses is more than additive. Addi-
tionally, LPS 1 Ova challenge induced inhaled corticosteroid
insensitivity of the allergen-driven responses such as eosino-
philia, which is associated with allergen rather than LPS
challenge.
LPS was administered by inhalation to the airways, likely
resulting in corticosteroid insensitivity mainly localized to
this tissue compartment. This result would limit the anti-
inflammatory activity of inhaled corticosteroids, which are
localized mainly in their distribution to the airways, particu-
larly in severe asthma (Wood et al., 1999; Brutsche et al., 2000;
Harrison and Tattersfield, 2003); however, a systemically
administered corticosteroid is distributed to tissues beyond
the lung including the blood and bone marrow, reducing
leukocytematuration andmigration to the airways from these
tissues (Mao et al., 2004; Ben et al., 2008). Thus, the
compartmentalization of corticosteroid insensitivity may
explain why lavage inflammatory cells are decreased by
systemic, but not by inhaled, corticosteroid in the Ova 1
LPS groups.
Neutrophils develop in the bone marrow and are recruited
to the airways from the systemic circulation (Wang and Arase,
2014). The sensitivity of neutrophils to corticosteroids differs
between the systemic circulation and the lung. In the lung,
neutrophils demonstrate decreased expression of glucocorti-
coid receptor-a compared with the blood and consequently are
relatively corticosteroid-insensitive in the airways (Plumb
et al., 2012).Therefore, i.p. dexamethasone, with a systemic
distribution, may reduce neutrophil numbers in a tissue
compartment where they are relatively sensitive to cortico-
steroids. In contrast, inhaled corticosteroids demonstrate low
systemic distribution (Wood et al., 1999; Martin et al., 2002;
Shen et al., 2002). Thus, in the current study, the reduction in
neutrophils with systemic, but not inhaled, dexamethasone
in Ova 1 LPS and LPS groups may be due to differences in
corticosteroid distribution. The corticosteroid insensitivity of
lung neutrophils may be further exacerbated in conditions of
high oxidative stress as a result of reduced histone deacetylase
transferase-2 activity and increased expression of glucocorti-
coid receptor-a, decreasing corticosteroid sensitivity (Hamilos
et al., 2001; Ito et al., 2004; Mercado et al., 2011). Thus, the
elevatedneutrophil numbers present inOva1LPS–challenged
guinea pigs may represent a distinct corticosteroid-insensitive
lung neutrophil population, supported by the continued eleva-
tion of lung IL-8 levels, which were not reduced by systemic
dexamethasone (Trapp et al., 1998).
Corticosteroid insensitivity does not seem to extend to the
increase in lavage fluid protein response to Ova 1 LPS, since
levels were decreased by inhaled and systemic dexametha-
sone. This finding suggests that differences in the sensitivity
of Ova 1 LPS responses to i.p. and inhaled dexamethasone
are not due to drug delivery issues and would be unlikely to
Fig. 6. Responses of airways to nebulized histamine
delivered in a plethysmograph (0.3 mM, 2 minutes) to
guinea pigs (A and B) sensitized and challenged with Ova
and treated with twice-daily inhaled (A) vehicle or (B)
dexamethasone (20 mg/ml); (C and D) sensitized and
challenged with Ova + LPS and treated with twice-daily
inhaled (C) vehicle or (D) dexamethasone (20 mg/ml); (E
and F) nonsensitized and challenged with LPS and treated
with once-daily inhaled (E) vehicle or (F) dexamethasone
20 mg/ml. Histograms represent the mean peak response to
histamine before and after Ova, Ova + LPS, or LPS
challenge. Mean changes in sGaw are expressed as mean6
S.E.M. percent change from baseline. A negative value
represents a bronchoconstriction. n = 6 or 7. *Significantly
different from vehicle treatment, P , 0.05; **P , 0.01;
***P , 0.001; performed with a two-tailed t test.
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account for the large differences in anti-inflammatory action
between these two routes of administration.
This study has demonstrated that the LAR, AHR, airway
inflammation (eosinophils and macrophages), lung cytokines
(IL-13 and IL-17), and lavage fluid protein levels induced by
Ova alone are sensitive to inhaled and systemic dexametha-
sone. The addition of LPS to the Ova exposure abolished the
effect of inhaled dexamethasone on these parameters. It also
reduced the effectiveness of systemic dexamethasone on the
LAR and AHR. Have our results with inflammatory cytokines
thrown further insight into the site of steroid resistance? The
generation of IL-8, IL-13, and IL-17 by Ova 1 LPS was
resistant to both systemic and inhaled steroid; however,
neutrophils were inhibited by systemic dexamethasone but
not by the neutrophil chemoattractants IL-8 and IL-17.
Therefore the site of steroid action on neutrophil migration
must be independent of these cytokines, possibly on neutro-
phil survival through inhibition of their apoptosis (Meagher
et al., 1996. The insensitivity of IL-13 and AHR to both routes
of administration after Ova 1 LPS indicates that AHR re-
sistance is linked to events above IL-13 generation in the
inflammatory cascade possibly at the site of Th2 cells. These
results suggest that the route of corticosteroid administration
may be important in determining the sensitivity of asthmatic
responses to these agents. These results reflect the clinical
situation, where patients who are insensitive to inhaled
Fig. 7. Total cell (A), macrophage (B), eosinophil (C), lymphocyte (D), and neutrophil (E) counts and lavage fluid protein levels (F) in the bronchoalveolar
fluid and IL-8, (G), IL-13 (H), and IL-17 (I). Guinea pigs were sensitized and challenged with Ova, sensitized with Ova, and challenged with Ova + LPS or
nonsensitized guinea pigs challenged with LPS. Guinea pigs were treated with once-daily i.p. vehicle or dexamethasone (20 mg/kg). Results are
expressed as mean 6 S.E.M.; n = 6 or 7; *Significantly different from vehicle treatment, P , 0.05; **P , 0.01; ***P , 0.001; ^P , 0.05; ^^significantly
different from naïve, P ,0 .01; ^^^P , 0.001; performed with a two-tailed t test or Mann-Whitney U test where appropriate.
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corticosteroids frequently demonstrate some sensitivity to
systemic corticosteroids. This suggests that the Ova 1 LPS
model is clinically relevant and may facilitate better modeling
of corticosteroid insensitivity in asthma, currently an area of
unmet clinical need.
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